If I were you I'd worry about something else. Consider 9 of 32 reps have left YTD. The product is in it's 5th year with no indication change for another two years while an oral will be available in one. A weak pipeline. And finally, 6 of 8 MSLs have left because they didn't like being treated like sales reps. They can't hire new MSLs because MSLs aren't stupid so they have to expand the sales force. The expansion is short-term. And one more thing; there are rumors of acquisition.
